Request Demo
Last update 25 Jul 2025
AZD-6793
Last update 25 Jul 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms AZD 6793, AZD6793 |
Target |
Action inhibitors |
Mechanism IRAK4 inhibitors(Interleukin-1 receptor-associated kinase 4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
4
Clinical Trials associated with AZD-6793NCT07082738
A Multicentre, Parallel-group, Phase IIb, Randomised, Double-blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO)
NCT06494644
An Open-label, Single-group, Three-period, Fixed-sequence, Phase I Study to Assess the Pharmacokinetics of AZD6793 Tablets When Administered Alone and in Combination With Itraconazole Capsules in Healthy Adult Female and Male Participants.
NCT06368440
A Single-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of an Oral Suspension of AZD6793 Following Single and Multiple Doses in Japanese and Chinese Healthy Participants
100 Clinical Results associated with AZD-6793
Login to view more data
100 Translational Medicine associated with AZD-6793
Login to view more data
100 Patents (Medical) associated with AZD-6793
Login to view more data
100 Deals associated with AZD-6793
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Pulmonary Disease, Chronic Obstructive | Phase 2 | United States | 27 Jun 2025 | |
| Pulmonary Disease, Chronic Obstructive | Phase 2 | China | 27 Jun 2025 | |
| Pulmonary Disease, Chronic Obstructive | Phase 2 | Japan | 27 Jun 2025 | |
| Pulmonary Disease, Chronic Obstructive | Phase 2 | Argentina | 27 Jun 2025 | |
| Pulmonary Disease, Chronic Obstructive | Phase 2 | Australia | 27 Jun 2025 | |
| Pulmonary Disease, Chronic Obstructive | Phase 2 | Bulgaria | 27 Jun 2025 | |
| Pulmonary Disease, Chronic Obstructive | Phase 2 | Canada | 27 Jun 2025 | |
| Pulmonary Disease, Chronic Obstructive | Phase 2 | Chile | 27 Jun 2025 | |
| Pulmonary Disease, Chronic Obstructive | Phase 2 | Denmark | 27 Jun 2025 | |
| Pulmonary Disease, Chronic Obstructive | Phase 2 | Germany | 27 Jun 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free